PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2014.1062015474796-803Can Serum be Used for Analyzing the <i>KRAS</i> Mutation Status in Patients with Advanced Colorectal Cancer?Seung Tae Kim, Won Jin Chang, Lihua Jin, Jae Sook Sung, Yun Ji Choi, Yeul Hong Kimhttp://e-crt.org/upload/pdf/crt-2014-106.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.106, http://www.e-crt.org/upload/pdf/crt-2014-106.pdf
European Journal of Cancer10.1016/s0959-8049(11)72448-0201147S6349136 POSTER Can Serum Be Used for Analyzing the EGFR Mutation Status in Patients With Advanced Non-Small Cell Cancer (NSCLC)?S. Kim, H. Jung, J. Sung, U. Jo, Y. Kim, S. Shin, T. Tanaka, K. Hagiwara, Y. Choihttps://api.elsevier.com/content/article/PII:S0959804911724480?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804911724480?httpAccept=text/plain
Clinical Colorectal Cancer10.1016/j.clcc.2011.10.005201211285-87To Give or Not to Give Anti–Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies to Patients With KRAS G13D Mutation in Advanced Colorectal CancerRichard Kim, Timothy Kubalhttps://api.elsevier.com/content/article/PII:S1533002811001319?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002811001319?httpAccept=text/plain
10.21203/rs.3.rs-23443/v1202018 F-FDG uptake heterogeneity predicts KRAS/NRAS/BRAF mutation status in patients with liver metastases of colorectal cancerGuang Ma, Fangsong Zhang, Qiufang Liu, Lingling Pan, Jianping Zhang, Yingjian Zhang, Shaoli Songhttps://www.researchsquare.com/article/rs-23443/v1, https://www.researchsquare.com/article/rs-23443/v1.html
10.21203/rs.3.rs-49998/v12020Clinic-pathological characteristics of MMR protein, KRAS-NRAS-BRAF gene mutation, HER-2 and PD-L1 status in 3822 Chinese colorectal cancer patientsLi Zhang, Nan Chen, Zhongwu Li, Aiwen Wu, Jie Chenhttps://www.researchsquare.com/article/rs-49998/v1, https://www.researchsquare.com/article/rs-49998/v1.html
International Journal of Colorectal Disease10.1007/s00384-012-1525-42012285733-734Letter to the Editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutationPeihao Yin, Yanyan Qiu, Qi Lihttp://link.springer.com/content/pdf/10.1007/s00384-012-1525-4.pdf, http://link.springer.com/article/10.1007/s00384-012-1525-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00384-012-1525-4
Clinical Colorectal Cancer10.1016/j.clcc.2019.05.0042019184e309-e315KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal CancerNirit Yarom, Gillian Gresham, Nana Boame, Derek Jonkerhttps://api.elsevier.com/content/article/PII:S1533002819300295?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002819300295?httpAccept=text/plain
Clinical Colorectal Cancer10.3816/ccc.2010.n.00320109122-30KRAS Mutation Screening in Colorectal Cancer: From Paper to PracticeMarwan M. Fakihhttps://api.elsevier.com/content/article/PII:S1533002811700299?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002811700299?httpAccept=text/plain
Cancer10.1002/cncr.300852016122172698-2707Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastasesGeorgios A. Margonis, Yuhree Kim, Kazunari Sasaki, Mario Samaha, Neda Amini, Timothy M. Pawlikhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.30085, https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30085
Scientific Reports10.1038/s41598-019-53039-y201991Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patientsZhouhuan Dong, Linghong Kong, Zhiyi Wan, Fengwei Zhu, Mei Zhong, Yali Lv, Po Zhao, Huaiyin Shihttp://www.nature.com/articles/s41598-019-53039-y.pdf, http://www.nature.com/articles/s41598-019-53039-y, http://www.nature.com/articles/s41598-019-53039-y.pdf